Back to results
US 6,270,981 B1Granted
Methods of screening competitors of OB-R binding to SHP-2-SH2 peptides
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLaura R. Carpenter, Neil Stahl, George D. Yancopoulos
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for identifying therapeutic agents that enhance the effect of leptin, an adipocyte-derived cytokine that regulates food intake and body weight. The invention further provides for use of agents identified using this assay system to enhance the interaction between leptin and its receptor, OB-R, thereby boosting leptin's weight-reducing effects in obese individuals.
Claims5
A method of screening for a molecule capable of competing with OB-R for binding to Src homology 2 containing protein tyrosine phosphatase 2 (SHP-2) comprising:
- a) contacting an OB-R phosphopeptide comprising the Y986 domain of the OB-R of SEQ ID NO:
- 1 under conditions in which the OB-R phosphopeptide is capable of binding to an SHP-2-SH2 peptide comprising src homology domain 2 of SHP-2;
- b) determining the amount of the OB-R phosphopeptide that binds to the SHP-2-SH2 peptide;
- c) contacting a known amount of the OB-R phosphopeptide to the SHP-2-SH2 peptide, in the presence of a sample suspected of containing the molecule capable of competing with the OB-R phosphopeptide, under the same conditions used in b);
- d) determining the amount of the OB-R phosphopeptide that binds to the SHP-2-SH2 peptide;
- and
- e) comparing the amount from (b) with the amount from (d), wherein a lesser amount in (d) indicates the presence of a molecule capable of competing with the OB-R phosphopeptide for binding to the SHP-2-SH2 peptide.
4 more elements
Dependencies are inferred from the claim text.